This morning, the president, who personally named this IndoVac vaccine, officially unveiled the IndoVac vaccine and directly witnessed the first administration of the IndoVac vaccine for residents, who have not been administered at all
Bandung, West Java (ANTARA) – The first administration of COVID-19 vaccine IndoVac targeted residents, who had not received a vaccine at all, State-run Pharmaceutical Company PT Bio Farma President Director Honesti Basyir stated at the Bio Farma Office, here, Thursday.
According to Basyir, the clinical trial performed for the IndoVac vaccine that received the emergency use authorization (EUA) certification only applies for primary-stage vaccination.
“This morning, the president, who personally named this IndoVac vaccine, officially unveiled the IndoVac vaccine and directly witnessed the first administration of the IndoVac vaccine for residents, who have not been administered at all,” he said.
Related news: IndoVac vaccine is first COVID-19 vaccine produced in Indonesia: BPOM
The first administration of the IndoVac vaccine was conducted for around 15 people.
While it is only for primary vaccination, Bio Farma is also striving to receive the IndoVac vaccine EUA for the booster vaccination stage to reduce import dependency.
“If the clinical trial is completed, and it receives an authorization from the POM (Food and Drug Supervisory) Agency, then this would be used for the government’s booster program,” Basyir stated.
He made assurance that the IndoVac vaccine is of the same quality as the other frequently used vaccines, with efficacy of over 80 percent. What is most important is that the IndoVac vaccine has a halal certificate.
Related news: Bio Farma to produce 20 mln IndoVac doses after EUA clearance
Since the matter of halal is important in Indonesia, Bio Farma has designed this vaccine with sound safety, high efficacy, good quality, and halal from the start, he noted.
Earlier, President Joko Widodo (Jokowi) unveiled the IndoVac vaccine, which is a domestic production from upstream to downstream.
Bio Farma can currently produce the IndoVac vaccine, with a capacity of 20 million doses. Meanwhile, for 2023, up to 40 million doses of the IndoVac vaccine can be produced, the president remarked.
Related news: Jokowi launches domestically manufactured IndoVac COVID-19 vaccine
Related news: Bio Farma’s IndoVac vaccine obtains BPJPH’s halal certificate